Bilthoven Biologicals
Eric Van Gerven has extensive experience in project management and leadership within the biotechnology sector, currently serving as a Project Manager at Bilthoven Biologicals since July 2012. Prior roles include Project Leader at the Netherlands Vaccine Institute from 2005 to June 2012 and Plant Manager at Nederlands Vaccin Instituut between 2000 and July 2005. Eric holds a degree in Chemical Engineering from Delft University of Technology and a degree in Food Technology from HAS Green Academy, complementing business acumen gained at Nyenrode Business University in 2000.
This person is not in any offices
Bilthoven Biologicals
About Bilthoven Biologicals Bilthoven Biologicals is a biopharmaceutical company which produces Inactivated Polio Vaccines (IPV), Tetanus Vaccines, Diphtheria-Tetanus-Polio Vaccines (DT-PV) and Bacillus Calmette-Guérin (BCG) for the treatment of bladder cancer. We deliver our vaccines to UNICEF, with which we support the World Health Organisation (WHO) to eradicate polio. Bilthoven Biologicals has been part of the Cyrus Poonawalla Group since 2012, the world’s largest vaccine producer and employs more than 500 employees. www.bbio.nl | www.werkenbijbbio.nl | https://www.bbio.nl/en/what-we-produce/report-side-effects/ Over Bilthoven Biologicals Bilthoven Biologicals is een biofarmaceutisch bedrijf dat geïnactiveerde polio vaccins (IPV), Tetanus vaccins, Difterie-Tetanus-Polio vaccins (DT-IPV) produceert en Bacillus Calmette-Guérin (BCG) voor de behandeling van blaaskanker. Wij leveren onze vaccins aan UNICEF, waarmee wij de Wereldgezondheidsorganisatie (WHO) ondersteunen bij het uitroeien van polio. Bilthoven Biologicals is sinds 2012 onderdeel van de Cyrus Poonawalla Group, de grootste vaccinproducent ter wereld en heeft ruim 500 medewerkers. www.bbio.nl | www.werkenbijbbio.nl | https://www.bbio.nl/wat-wij-maken/bijwerkingen-melden/